全文获取类型
收费全文 | 51160篇 |
免费 | 4580篇 |
国内免费 | 714篇 |
专业分类
耳鼻咽喉 | 189篇 |
儿科学 | 567篇 |
妇产科学 | 867篇 |
基础医学 | 4742篇 |
口腔科学 | 299篇 |
临床医学 | 6072篇 |
内科学 | 3554篇 |
皮肤病学 | 446篇 |
神经病学 | 3911篇 |
特种医学 | 3123篇 |
外国民族医学 | 6篇 |
外科学 | 7928篇 |
综合类 | 5979篇 |
预防医学 | 2736篇 |
眼科学 | 323篇 |
药学 | 3291篇 |
20篇 | |
中国医学 | 844篇 |
肿瘤学 | 11557篇 |
出版年
2024年 | 51篇 |
2023年 | 648篇 |
2022年 | 1205篇 |
2021年 | 1927篇 |
2020年 | 1913篇 |
2019年 | 1663篇 |
2018年 | 1816篇 |
2017年 | 1938篇 |
2016年 | 1899篇 |
2015年 | 1984篇 |
2014年 | 3595篇 |
2013年 | 3788篇 |
2012年 | 3147篇 |
2011年 | 3346篇 |
2010年 | 2620篇 |
2009年 | 2803篇 |
2008年 | 2875篇 |
2007年 | 2821篇 |
2006年 | 2334篇 |
2005年 | 1900篇 |
2004年 | 1603篇 |
2003年 | 1370篇 |
2002年 | 1114篇 |
2001年 | 1043篇 |
2000年 | 862篇 |
1999年 | 703篇 |
1998年 | 702篇 |
1997年 | 617篇 |
1996年 | 511篇 |
1995年 | 534篇 |
1994年 | 430篇 |
1993年 | 319篇 |
1992年 | 278篇 |
1991年 | 227篇 |
1990年 | 194篇 |
1989年 | 198篇 |
1988年 | 152篇 |
1987年 | 159篇 |
1986年 | 136篇 |
1985年 | 190篇 |
1984年 | 157篇 |
1983年 | 108篇 |
1982年 | 133篇 |
1981年 | 133篇 |
1980年 | 117篇 |
1979年 | 64篇 |
1978年 | 38篇 |
1977年 | 26篇 |
1976年 | 23篇 |
1975年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 500 毫秒
21.
《Radiologia》2022,64(3):256-265
Breast cancer is the second most common cancer in Peruvian women. Due to limitations in national breast cancer screening programs, especially in rural areas, more than 50% of cases of breast cancer in Peru are diagnosed in advanced stages. In collaboration with a local clinic registered as a nongovernmental organization (CerviCusco), RAD-AID International aims to create a sustainable diagnostic structure to improve breast cancer screening in Cuzco. With the support of local, national, and international partners that have collaborated in analyzing radiological resources, raising awareness in the population, acquiring equipment, training clinical staff, and building referral networks, our teams of radiologists, included in the RAD-AID team, have participated in training CerviCusco staff in breast ultrasound, thus enabling additional training for radiology residents through a regulated international collaboration. 相似文献
22.
23.
24.
25.
《Clinical breast cancer》2020,20(5):e576-e583
BackgroundThe objective of this study was to assess the detection and accuracy of sentinel lymph node (SLN) biopsy (SLNB) using the low-cost indocyanine green (ICG) fluorescence method and to compare this method with the gold standard dual-dye method (radio-colloid + methylene blue dye [MB]).Materials and MethodsOne hundred patients with node-negative early breast cancer assessed clinically and by ultrasound axilla underwent an SLNB procedure using technetium-99m radio-colloid, MB, and ICG. The detection rate of SLNs and positive SLNs and the number of SLNs were compared. The injection safety of ICG and MB was evaluated.ResultsOne hundred female patients with a median age of 52.3 years participated in the study. Sixty-eight percent had a body mass index < 25, 85% presented with a palpable lump, of which 59% were in the outer quadrant. SLNs were identified in all 100 cases. A total of 290 SLNs were removed (mean, 2.9; range, 1-6). The identification rate with dual dye was 94%, whereas with ICG alone, it was 96%. The SLNB sensitivity rate and false negative rate were 97.6% versus 93.2% and 3.1% versus 6.2% in the ICG and dual-dye combination, respectively. None of the patients had any local or systemic reaction with ICG; 3 patients with blue dye had tattooing and staining of skin.ConclusionICG fluorescence imaging permits real time visualization of lymphatics and provides an additional dimension to SLN biopsy that is safe and effective. These results confirm high sensitivity for fluorescence localization with comparable performance to the gold standard. ICG can reliably replace dual dye and be employed as a sole tracer for SLNB in early breast cancer. 相似文献
26.
目的观察多西紫杉醇联合吡柔比星化疗在乳腺癌患者治疗中的效果,及对不良反应发生率的影响。方法选取乳腺癌患者为研究对象,并根据其化疗药物的不同分为对照组和观察组,对照组给予紫杉醇联合吡柔比星进行化疗,观察组给予多西紫杉醇联合吡柔比星进行化疗。观察2组患者的治疗效果、不良反应发生率和复发率,比较2组患者治疗前后肿瘤标志物水平的差异。结果观察组治疗有效率为97. 50%,明显高于对照组的80. 00%,差异有统计学意义(χ^2=6. 135,P=0. 013)。2组患者治疗前肿瘤标志物水平无差别,治疗后,观察组患者的CEA、CA125、CA153水平低于对照组(t=11. 432、18. 876、3. 703,P <0. 001)。2组患者骨髓抑制、恶心呕吐、脱发、中性粒细胞减少、肝功能损害等不良反应发生率无差别(χ^2=0. 238,P=0. 626)。对照组1年复发率较观察组高,但差异无统计学意义(χ^2=1. 053,P=0. 305)。结论多西紫杉醇联合吡柔比星化疗对乳腺癌患者的化疗效果较好,且不会增加骨髓抑制等不良反应发生率,具有良好的应用价值。 相似文献
27.
Mark Verrill 《Surgery (Oxford)》2019,37(3):181-185
Multimodality primary therapies for breast cancer combined with earlier detection have led to a sharp decline in the death rate from breast cancer in the UK over the last 40 years in the face of a rising incidence. The latest UK statistics from Cancer Research UK report 55,122 new cases of breast cancer in 2015 with 11,563 deaths from breast cancer recorded in 2016. Crudely, this equates to a cure rate of around 80% for all comers and demonstrates a clear improvement in outcome with 50,285 new cases in 2011 and 11,716 deaths in 2012. Despite this good news, there are still significant numbers of women (and men) who suffer from either a local recurrence or metastatic disease following apparently successful treatment for early breast cancer (Stage I to III). Only a minority of individuals, 6.6% with the stage recorded at diagnosis, present with stage IV disease. This review considers the treatment options available to individuals with locally recurrent and advanced breast cancer (ABC). 相似文献
28.
HER2-positive (HER2+) breast cancer (BC) is a heterogenous and multifaceted disease, with interesting therapeutic implications. First, all intrinsic molecular subtypes can be identified in HER2+ tumors, with the HER2-enriched being the most frequent. Such subtypes do not differ much from their counterparts in HER2-negative disease, apart for the high expression of genes in/near the HER2 amplicon on chromosome 17. Intrinsic subtyping, along with the quantification of ERBB2 mRNA levels, is associated with higher rates of pathologic complete response across neoadjuvant trials of dual HER2 blockade and might help select patients for de-escalation and escalation treatment strategies. Secondly, HER2+ tumors have a broad range of DNA alterations. ERBB2 mutations and alterations in the PI3K/Akt/mTOR pathway are among the most frequent and might predict benefit from potent pan-HER, PI3K and mTOR inhibitors. Moreover, HER2+ tumors are usually infiltrated by lymphocytes. These tumor infiltrating-lymphocytes (TILs) predict response to neoadjuvant anti-HER2-based treatment and exert a prognostic role. PD-L1, detected in ∼42 % of HER2+ BC, might also be useful to define patients responding to novel anti-PD1/PD-L1 immunotherapies. New multiparametric clinicopathologic and genomic tools accounting for this complexity, such as HER2DX, are under development to define more tailored treatment approaches. Finally, HER2-targeted antibody-drug conjugates (ADC) such as trastuzumab deruxtecan might be active in tumors with low expression of HER2. Overall, there is a need to molecularly characterize and develop novel targeted therapies for HER2+ disease. 相似文献
29.
Elisa Malacarne Marta Devesa Francisca Martinez Ignacio Rodriguez Buenaventura Coroleu 《Journal of assisted reproduction and genetics》2020,37(12):3069
PurposeBreast cancer is the most common cancer diagnosed during childbearing age, and fertility preservation is becoming increasingly more essential. However, recent studies indicate a possible poorer response to controlled ovarian hyperstimulation (COH) in cancer patients than in non-cancer controls and a negative impact of BRCA mutations on female fertility. This study aims to evaluate ovarian response and the number of mature oocytes (MII) vitrified in women with breast cancer, with or without BRCA mutation, comparing them to the expected response according to an age-related nomogram.MethodsThis is a retrospective observational study involving sixty-one breast cancer patients who underwent COH for oocyte cryopreservation. The age-specific nomogram was built using 3871 patients who underwent COH due to oocyte donation, fertility preservation for non-medical reasons, or FIVET for male factor exclusively.ResultsThe mean number of oocytes retrieved was 13.03, whereas the mean number of MII oocytes was 10.00. After the application of the z-score, no statistically significant differences were found compared with the expected response in the general population, neither by dividing patients according to the presence or absence of BRCA mutation nor according to the phase in which they initiated stimulation.ConclusionThe results obtained do not support the notion of a negative impact of the BRCA mutation on the ovarian response of women with breast cancer. Women with breast cancer undergoing COH for fertility preservation can expect the ovarian response predicted for their age. 相似文献
30.
Moises Rodriguez-Gonzalez Antonio Moruno Tirado Reza Hosseinpour Jose Santos de Soto 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(4):350-356
Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) is a rare congenital condition. It responds well to early diagnosis and treatment, but otherwise the prognosis is poor. We present our case series of 12 patients (mean age, 2 ± 2.58 yr; age range, 2 mo–8 yr), emphasizing the diagnostic process and discussing our surgical results. The diagnosis of ALCAPA should be suspected in infants who have dilated cardiomyopathy with electrocardiographic changes that suggest ischemia, and in older children who have isolated mitral regurgitation. When clinical suspicion is high, the results of 2-dimensional echocardiography combined with color-flow Doppler studies in expert hands can establish the diagnosis, thus avoiding angiography in critically ill infants. The treatment of choice in our patients was transfer and reimplantation of the left coronary artery onto the ascending aorta. There were 2 deaths: both were infants in extremis who underwent emergency surgery. An older child with severe ventricular dysfunction was given mechanical ventricular assistance and then heart transplantation. As of this report, all 10 survivors remained well and asymptomatic. 相似文献